A Clinical Study of Sintilimab Independently or in Combination With IBI310 (Anti-CTLA4) in Second-Line Cervical Cancer
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, controlled, parallel-cohort Phase II clinical study,
which is planned to enroll 174 subjects with advanced cervical cancer who have failed or
cannot tolerate first-line or above platinum-based chemotherapy